WO2003090744A1 - Antibacterial compositions comprising metal phthalocyanine analogues - Google Patents

Antibacterial compositions comprising metal phthalocyanine analogues Download PDF

Info

Publication number
WO2003090744A1
WO2003090744A1 PCT/EP2003/004080 EP0304080W WO03090744A1 WO 2003090744 A1 WO2003090744 A1 WO 2003090744A1 EP 0304080 W EP0304080 W EP 0304080W WO 03090744 A1 WO03090744 A1 WO 03090744A1
Authority
WO
WIPO (PCT)
Prior art keywords
phthalocyanine
compound
zinc
tetra
group
Prior art date
Application number
PCT/EP2003/004080
Other languages
French (fr)
Other versions
WO2003090744A8 (en
Inventor
Gabrio Roncucci
Donata Dei
Giacomo Chiti
Lia Fantetti
Francesco Giuliani
Giulio Jori
Gian Maria Rossolini
Original Assignee
L. Molteni & C. Dei Fratelli Alitti Societa' Di Esercizio S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by L. Molteni & C. Dei Fratelli Alitti Societa' Di Esercizio S.P.A. filed Critical L. Molteni & C. Dei Fratelli Alitti Societa' Di Esercizio S.P.A.
Priority to JP2003587378A priority Critical patent/JP2005524692A/en
Priority to IL16480103A priority patent/IL164801A0/en
Priority to CA2484070A priority patent/CA2484070C/en
Priority to US10/512,287 priority patent/US8664382B2/en
Priority to AU2003224100A priority patent/AU2003224100B2/en
Publication of WO2003090744A1 publication Critical patent/WO2003090744A1/en
Publication of WO2003090744A8 publication Critical patent/WO2003090744A8/en
Priority to ZA2004/09452A priority patent/ZA200409452B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/315—Zinc compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/695—Silicon compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
    • C09B47/00—Porphines; Azaporphines
    • C09B47/04—Phthalocyanines abbreviation: Pc
    • C09B47/045—Special non-pigmentary uses, e.g. catalyst, photosensitisers of phthalocyanine dyes or pigments
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
    • C09B47/00—Porphines; Azaporphines
    • C09B47/04—Phthalocyanines abbreviation: Pc
    • C09B47/08—Preparation from other phthalocyanine compounds, e.g. cobaltphthalocyanineamine complex
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • the present invention relates to pharmaceutical compositions comprising the metal phthalocyanine analogues of formula (I) hereinafter reported and metal chelating compounds, having a good bioavailability and enhanced photodynamic properties, useful for the treatment of infectious diseases and for in vivolex vivo applications.
  • metal chelating compounds having a good bioavailability and enhanced photodynamic properties, useful for the treatment of infectious diseases and for in vivolex vivo applications.
  • phthalocyanines are molecules able to produce singlet oxygen in good yields as a result of light irradiation and have therefore photoenhanced biocidal activity. The biocidal properties of such molecules, once properly directed, make these molecules extremely interesting for therapeutic applications.
  • Zn(ll)-phthalocyanines and other metal-phthalocyanines having applications in photodynamic therapy (PDT) and diagnosis, have been recently described in the US Patent No.
  • non cationic compounds having either a porphyrin or a phthalocyanine nucleus, do not show any efficacy against Gram negative unless administered in the presence of additional substances capable of altering the permeability of the outer membrane; Ca 2+ salts, Tris-EDTA, etc., have been used to this aim.
  • metal chelating agents in particular metal chelating agents naving specificity for the Ca 2+ and Mg 2+ ions, such as 1 ,2-diaminocyclohexane- N,N,N',N'-tetraacetic acid (CDTA), diethylenetriamine-pentaacetic acid (DTPA) and ethylenediaminetetraacetic acid (EDTA).
  • compositions comprising at least a metal phthalocyanine analogue of formula (I)
  • n O, 1 or 2;
  • M is chosen in the; group consisting of Zn, Si(OR 3 ) 2 and AIOR 3 wherein R 3 is chosen in the group, consisting of H and C ⁇ . ⁇ 5 alkyl; R is chosen from H and W, wherein W is represented by the group (X) P R 4 , wherein:
  • X is preferably chosen in the group consisting of O, S, -NR and -CH 2 -; and R is
  • Y is chosen in the group consisting of C O alkyl and phenyl, possibly substituted, or it forms with the Z group, to which it is bound, a saturated or unsaturated heterocycle, possibly substituted, which may contain up to two heteroatoms chosen in the group consisting of N, O and S;
  • Z is chosen in the group consisting of -N, -CH 2 N and -CONHCH 2 CH 2 N; R 5 and R ⁇ , equal or different from one another, are chosen in the group consisting of C ⁇ .
  • R and R 8 equal or different from one another, are chosen in the group consisting of H and C ⁇ .
  • 15 alkyl ; m, n, p, s, t and u, independently from one another, are 0 or 1 ; and
  • v is an integer comprised between 1 and 3;
  • Ri and R 2 are chosen from H, W and K, wherein W is as defined above, and K is selected from the group consisting of -
  • R 2 is in the position 1(4) or 2(3); in combination with at least a metal chelating agent.
  • Figure 1 shows the variation of CFU (colony forming units) of E. co// ATCC 25922 (Log CFU) vs. concentration ( ⁇ M) of the compound ⁇ 2,3,9,10,16,17,23,24-octa[3-
  • compound 1 when a population of 6.6x10 6 CFU in
  • Figure 2 shows the variation of CFU of E. coli ATCC 25922 (Log CFU) vs. concentration ( ⁇ M) of the formulation according to the invention comprising the compound 1 in combination with EDTA 0.5 mM, when a population of 1.0x10 7 CFU in 100 ⁇ L is incubated for 5 minutes with the above said formulation.
  • Figure 2a shows the variation of CFU of E. coli ATCC 25922 (Log CFU) vs. concentration ( ⁇ M) of the formulation according to the invention comprising the compound 1 in combination with CDTA 0.5 ⁇ M, when a population of 6.6x10 6 CFU in 100 ⁇ L is incubated for 5 minutes with the above said formulation.
  • Figure 2b shows the variation of CFU of E. coli ATCC 25922 (Log CFU) vs. concentration ( ⁇ M) of the formulation according to the invention comprising the compound 1 in combination with DTPA 0.5 mM, when a population of 3.3x10 6 CFU in 100 ⁇ L is incubated for 5 minutes with the above said formulation.
  • Figure 3 shows the variation of CFU of Pseudomonas aeruginosa PAO-1 (Log
  • Figure 3a shows the variation of CFU of P. aeruginosa PAO-1 (Log CFU) vs. concentration ( ⁇ M) of the present formulation comprising the compound 1 in combination with EDTA 0.5 mM, when a population of 6.6x10 6 CFU in 100 ⁇ L is incubated for 5 minutes with the above said formulation.
  • Figure 3b shows the variation of CFU of P. aeruginosa PAO-1 (Log CFU) vs. concentration ( ⁇ M) of the formulation of the invention comprising the compound 1 in combination with CDTA 0.5 mM, when a population of 6.6x10 6 CFU in 100 ⁇ L is incubated for 5 minutes with the above said formulation.
  • Figure 3c shows the variation of CFU of P. aeruginosa PAO-1 (Log CFU) vs. concentration ( ⁇ M) of the present formulation comprising the compound 1 in combination with DTPA 0.5 mM, when a population of 6.6x10 6 CFU in 100 ⁇ L is incubated for 5 minutes with the above said formulation.
  • Figure 4 shows the variation of CFU of P. aeruginosa PAO-1 (Log CFU) vs. concentration ( ⁇ M) of the present formulation comprising the compound 1 in combination with EDTA 0.5 mM, at different irradiation times with 50 mW/cm 2 of red light, when a population of 1.0x10 7 CFU in 100 ⁇ L is incubated with the above said formulation.
  • Figure 5 shows the variation of CFU of E. coli ATCC 25922 (Log CFU) vs. concentration ( ⁇ M) of the present formulation comprising the compound
  • compound 2 ⁇ 2(3),9(10),16(17),23(24)-tetra[1 ,3-ib/s-(trimethylammonium)propyl-2-oxy] zinc(ll) hthalocyanine ⁇ octaiodide (hereinafter referred to as "compound 2”) in combination with EDTA 0.5 mM, when a population of 6.6x10 6 CFU in 100 ⁇ L is incubated for 5 minutes with the above said formulation.
  • Figure 5a shows the variation of CFU of E. coli ATCC 25922 (Log CFU) vs. concentration ( ⁇ M) of the present formulation comprising the compound 2, when a population of 1.0x10 7 CFU in 100 ⁇ L is incubated for 5 minutes with the above said formulation.
  • Figure 6 shows the variation of CFU of P. aeruginosa PAO-1 (Log CFU) vs. concentration ( ⁇ M) of a formulation comprising the compound 1 in combination with polymixine B sulphate 50 mM, at different irradiation times with 50 mW/cm 2 of red light, when a population of 1.0x10 7 CFU in 100 ⁇ L is incubated for 5 minutes with the above said formulation.
  • the present invention allows to provide novel pharmaceutical compositions directed to the inactivation of Gram negative bacteria with enhanced physical- chemical and photodynamic properties thanks to the combination of the metal phthalocyanine analogues of formula (I) as above defined with at least a metal chelating agent.
  • suitable linker is intended in the sense commonly given to this definition in the field of protein and nucleic acid modification (S.S. Wang, Chemistry of Protein Conjugation and Cross-linking CRC Press Inc. 1993, G.T. Hermanson Bioconjugate Techniques Academic Press, 1996), i.e. an aliphatic moiety which acts as a spacer between the phthalocyanine nucleus and the biological macromolecules, in order to satisfy the desired sterical and/or structural requirements.
  • saturated or unsaturated heterocycle possibly substituted the following are preferably meant : morpholine, piperidine, pyridine, pyrimidine, piperazine, pyrrolidine, pyrroline, imidazole, aniline, and julolidine (2,3,6,7-tetrahydro-1H,5H-pyrido[3,2,1-//]quinoline).
  • the preferred products are those in which the group (X) P R includes substituents bearing tertiary or quaternary nitrogen.
  • the said group (X) P R 4 is preferably represented by:
  • the metal phthalocyanine analogues to be used in combination with metal chelating agents in the pharmaceutical compositions of the invention are defined by the following formulas:
  • salts of the phthalocyanine compounds of the present invention include conventional acid addition salts, obtained by the addition of HCI, H 3 PO 4 , H 2 S0 4 , HBr, etc. Additionally, salts obtained by reaction of the carboxylic function or acid groups within the phthalocyanine ring are within the scope of the present invention. Such salts include, for example, salts of carboxylic and sulfonic acid with amine derivatives, basic amino acids and inorganic bases.
  • the phthalocyanine compounds of the present invention can be prepared according to reaction schemes that are known in organic chemistry.
  • the present compounds of formula (I) included in the cases d) and f) may be prepared as described in US Patent No. 5,965,598, which we incorporate herewith by reference; whereas the present compounds of formula (I) included in cases c), e) and g) may be prepared as described in the International Patent Application No. PCT/EP02/03108, which we incorporate herewith by reference; the present compounds of formula (I) of cases a) and b) may be prepared as described in the European Patent Application No. EP 00112654.9, which we incorporate herewith by reference.
  • the phthalocyanine compounds indicated above as compounds 1-24 have been already disclosed in the above said Patent Applications, whereas the compounds indicated above as compounds 25-33 have been newly prepared as described in the following examples.
  • the present compositions comprise at least a metal chelating agent, preferably selected from the metal chelating agents having specificity for the Ca 2+ and Mg 2+ ions, such as 1 ,2-diaminocyclohexane-N,N,N',N'-tetraacetic acid (CDTA), diethylenetriamine-pentaacetic acid (DTPA), ethylenediamine-N,N,N',N'-tetraacetic acid (EDTA), and salts thereof.
  • a metal chelating agent preferably selected from the metal chelating agents having specificity for the Ca 2+ and Mg 2+ ions, such as 1 ,2-diaminocyclohexane-N,N,N',N'-tetraacetic acid (CDTA), diethylenetriamine-penta
  • compositions according to the invention are those comprising
  • Photodynamic therapy using the phthalocyanine compounds formulated with the compound described in the present invention has a number of advantages.
  • the phthalocyanine compounds themselves are minimally toxic in the unexcited state.
  • Each phthalocyanine molecule can be repeatedly photoactivated and leads each time to cell-lethal events, that are the generation of singlet molecular oxygen or radicals.
  • the half-life of singlet oxygen is such that the target cell is affected without the opportunity for migration of the lethal singlet oxygen to neighbouring healthy tissue cells.
  • Singlet oxygen molecules target microorganism cell wall, or destroy intracellular structures, resulting in destruction of the target cell, without affecting chemical bonds in the cell DNA, at least at the doses which provide a complete photoinactivation.
  • Destruction of target cell tissue commences promptly upon irradiation of the phthalocyanine compounds and ceases abruptly when irradiation is stopped and, due to the non interference with DNA, a development of resistance in microorganisms is unlikely.
  • Photodynamic therapy with the compounds of the present invention is therefore selective and minimally toxic to healthy tissues.
  • the produced singlet oxygen molecules that do not react rapidly with neighbouring molecules rapidly decay.
  • a variety of phototherapy and irradiation methodologies are known to those skilled in the art and can be used with the phthalocyanine metal chelating derivatives of the present invention.
  • the time and duration of therapy and repetition of the irradiation treatment can be selected by the physician, according to known photodynamic therapy criteria.
  • the dosage of the phthalocyanine and the metal chelating compound in the present compositions may be varied, according to the size and location of the target tissues which are to be destroyed and the method of administration.
  • the dosage will be in the range between 0.1 and 20 mg of phthalocyanine compound per kilogram of body weight per day, more preferably in the range between 0.1 and 5.0 mg/kg.
  • the phthalocynine dosage will be in the range between 0.1 and 100 ⁇ g of compound per cm 2 of tissue, more preferably in the range between 1 and 10 ⁇ g/cm 2 .
  • the metal chelating compounds of the present invention may be administered in an amount ranging between 0.01 and 100 mg of the chelating compound per kilogram of body weight per day, and preferably in an amount ranging from 0.1 to 10 mg/Kg per day, in case of systemic administration, while a dosage between 0.1 and 100 ⁇ g/cm 2 per day, preferably in an amount ranging from 1 to 20 ⁇ g/cm 2 , will be used in case of topical deposition.
  • irradiation generally takes place not more than four days after systemic administration of the phthalocyanine compound.
  • phototherapy begins approximately 10 hours to 24 hours after systemic administration of the photodynamic therapy agent.
  • radiation therapy can commence immediately after topical application of the phthalocyanine or at any desired time up to 24 hours later.
  • Systemic application for treatment of dermatological diseases is followed by radiation usually 15 to 24 hours after systemic administration of the PDT agent.
  • Exposure to non therapeutic light sources should be avoided immediately following phototherapy, to minimize light toxicity. Appropriate protection of the patient can be used, to limit the area affected by phototherapy.
  • Light sources suitable for the use in PDT are well known in the art and may vary from white light sources associated with appropriate filters to lasers tuned to the right wavelength. As noted above, preferred wavelengths are from 600 to 950 nm, preferably from about 650 to about 750 nm.
  • the total amount of light which is applied to the affected area will vary with the treatment method used and with the location of the lesion. Generally, the amount of light is in the range of about 50 to 1000 J cm "2 , preferably in the range of 100 to 350 J cm "2 .
  • the present pharmaceutical compositions show valuable photodynamic characteristics and higher than the photosensitising agents previously described; these properties make them useful in photodynamic therapy (PDT) against bacterial, fungal and viral infections, in particular against Gram negative bacteria; as well as for sterilization of blood and blood derivatives, such as platelets and erythrocytes.
  • PDT photodynamic therapy
  • the present compositions can be added directly to blood or blood derivatives, or previously bound to suitable matrix, according to known techniques and, thereafter, irradiated.
  • EXAMPLE 1 ⁇ 2(3),9(10),16(17),23(24)-tetra[( ⁇ /-methyl-2,3,6,7-tetrahydro-1H,5H-pyrido[3,2,1-/7J quinolinium-8-yl)oxy)] phthalocyanine ⁇ zinc( . ll) iodide (compound 25) blue-green powder; formula: C 84 H 80 l 4 N 12 O 4 Zn; UV-Vis (DMF) ⁇ ma ⁇ (nm) 678 ( ⁇ -
  • Si(IV) phthalocyanine ⁇ octaiodide (compound 28) blue-green powder; formula: C 104 H ⁇ 14 l 8 N 16 O ⁇ oSi; UV-Vis (DMF) ⁇ max (nm) 677,
  • ⁇ 156.66, 153.35, 147.58, 142.06, 137.34, 136.80, 133.93, 129.74, 49.17.
  • compositions of the present invention has been evaluated through their activity against the Gram negative micro-organisms Pseudomonas aeruginosa PAO-1 and E. coli ATCC 25922. These microorganisms were used in the experiments in a stationary phase of growth.
  • the experimental protocol was the following:
  • the cell suspensions were diluted in an appropriate medium. Addition of an aliquot of stock solution of the composition to be tested to the cell suspension up to the intended final concentrations. Incubation in dark at 37 °C for 5 minutes. Irradiation (650 ⁇ ⁇ ⁇ 850 nm; 50 ⁇ 100 mW/cm2; 1 ⁇ 10 minutes) of cell suspension for each dilution of the photosensitising composition.
  • Figure 1 shows the photoinactivation of E. coli as a function of the concentration of the compound ⁇ 2,3,9,10,16,17,23, 24-octa[3-( ⁇ /, ⁇ /, ⁇ /-trimethylammonium)phenoxy] zinc(ll) phthalocyanine ⁇ octaiodide (compound 1).
  • Compound 1 can afford a 4 log reduction of the initial population, but a complete sterilization of the cell suspension cannot De obtained.
  • the inactivation can be performed by using lower fluence rates of light (50 mW/cm 2 ) and only 1 minute of irradiation (0.3 Jem "2 ) with 5 ⁇ M concentration is able to reduce the initial population by 4.5 log (see Figure 4).
  • Another example is provided by the use of the compound ⁇ 2(3),9(10),16(17),23(24)-tetra[1 ,3-jb/s-(trimethylammonium)propyl-2-oxy] zinc(ll) phthalocyanine ⁇ octaiodide (compound 2) against E. coli with and without EDTA (see respectively Figure 5 and 5a). It is clearly shown that the presence of EDTA enables the reduction of the photosensitizer concentration necessary to sterilize the cell suspension from 20 ⁇ M to 1 ⁇ M.
  • compositions as previously described may be administered by various routes, including parenteral or topical administration.
  • the present compositions can be used either for topical treatment of skin or mucosae diseases, as well as for the ex vivo treatments, such as blood or blood derivatives sterilization.
  • compositions according to the present invention include solutions, Jjposome or microvesicle preparations, dispersions, ointments and other suitable topical dermatological preparations, or preparations suitable for ex vivo applications.
  • compositions may comprise pharmacologically acceptable diluents or excipients.
  • Parenteral Solutions The photoactivatable phthalocyanines are generally used with additional solvents and adjuvants, to prepare solutions suitable for the in vivo or ex vivo administration.
  • additional solvents and adjuvants A number of solvents and co-solvents, that are miscible with water and suitable surfactants, can be used to achieve solutions for ex vivo application, assimilated to parenteral solutions and formulations.
  • the most important solvents in this group are ethanol, polyethylene glycols of the liquid series and propylene glycol.
  • a more comprehensive listing includes dimethyl sulfoxide, ethanol, glycerin, polyethylene glycol 300 and 400, propylene glycol, sorbitol, polyoxyethylene sorbitan, fatty acid esters such as laurate, palmitate, stearate and oleate, polyoxyethylated vegetable oil, sorbitan monopalmitate, 2-pyrrolidpne, N-methyl-2- pyrrolidine, N-ethyl-2-pyrrolidine and tetrahydrofurfuryl alcohol.
  • Other additives may be necessary to enhance or maintain chemical stability and physiological suitability. Examples are antidxidants, chelating agents, inert gases, buffers and isotonicifiers.
  • the phthalocyanine and enhancers compounds of the present invention may be formulated for topical application in penetrating solvents or in the form of a lotion, cream, ointment or gel, containing a sufficient amount of the phthalocyanine compound to be effective for PDT.
  • Suitable penetrating solvents are those which will enhance percutaneous penetration of the phthalocyanine compound.
  • Solvents having this property include dimethyl sulfoxide, 1-methyl-2-pyrrolidone, Azone ® , Transcutol ® , lauric acid and esters, essential oils, propylene glycol, ethanol and PEG at various molecular weights.
  • DMSO solutions containing 0-50 wt. % of water are particularly desirable.
  • Liposomes are microvesicles which encapsulate a liquid within lipid or polymeric membranes; the methods of preparing liposomes for both topical and parenteral (injectable) preparations are known in the art and can be used for the purposes of the present invention.
  • the present compositions having overall lipophilic characteristics may be incorporated into liposome microvesicles and used in this form for both topical and ex vivo applications.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to pharmaceutical compositions comprising metal phthalocyanine analogues of formula (I) and metal chelating compounds having a good bioavailability and enhanced photoinactivation properties against Gram negative bacteria; and to their use for in vivolex vivo applications, such as blood and blood derivatives sterilization.

Description

ANTIBACTERIAL COMPOSITIONS COMPRISING METAL PHTHALOCYANINE ANALOGUES Field of the invention
The present invention relates to pharmaceutical compositions comprising the metal phthalocyanine analogues of formula (I) hereinafter reported and metal chelating compounds, having a good bioavailability and enhanced photodynamic properties, useful for the treatment of infectious diseases and for in vivolex vivo applications. State of the art It is known that phthalocyanines are molecules able to produce singlet oxygen in good yields as a result of light irradiation and have therefore photoenhanced biocidal activity. The biocidal properties of such molecules, once properly directed, make these molecules extremely interesting for therapeutic applications. Zn(ll)-phthalocyanines and other metal-phthalocyanines, having applications in photodynamic therapy (PDT) and diagnosis, have been recently described in the US Patent No. 5,965,598, in the European Patent Applications No. 00112654.9, No. 01106411.0 and No. 01125770.6, all in the name of the Applicant, wherein this kind of compounds, their preparation processes and properties are also described. Despite the very high efficiency showed by the above mentioned phthalocyanines, in particular by cationic phthalocyanines, against the majority of micro-organisms, Gram negative bacteria still remain more difficult to inactivate. Even with the most active compounds described in the above cited patents and patent applications photoinactivation rates for Gram negative bacteria are at least one order of magnitude lower when compared to the inactivation of Gram positive bacteria and yeast, by using the same photosenεitizer and the same experimental conditions. On the other hand, non cationic compounds, having either a porphyrin or a phthalocyanine nucleus, do not show any efficacy against Gram negative unless administered in the presence of additional substances capable of altering the permeability of the outer membrane; Ca2+ salts, Tris-EDTA, etc., have been used to this aim.
However, it is worth mentioning that the available literature report only spared and contradictory information in this regard. In fact, while G. Bertoloni et al. in Photochem. Photobiol. (1984) 39, 811-816; Y Nitzan et al. Photochem. Photobiol. (1992) 55, 89-96, found that E. coli pretreated with 0.7 or 5 μM EDTA show a retained resistance to porphyrin and light, thus concluding that Gram negative bacteria are photoresistant even after the treatment with EDTA, in another paper G. Bertoloni et al. have obtained different results by using Tris EDTA in combination with a neutral and an anionic phthalocyanines against Gram negative bacteria (G. Bertoloni et al., FEMS Microbiology Letters, (1990) 71 , 149-156). In view of the above said, the need is deeply felt to provide novel pharmaceutical compositions and/or delivery systems, having photodynamic enhanced properties and an increased efficiency, especially against the specific pathologies caused by Gram negative bacteria. In this way, any undesired side effects can be avoided by lowering the dosage of the phthalocyanine photosensitizer, while retaining a high bacterial photoinactivation efficiency. Summary of the invention
The Applicant has now surprisingly found that phthalocyanines peripherally substituted in specific positions with cationic groups or with groups protonable at physiological pH.-are particularly effective in inducing the in vitro photoinactivation in conjunction with metal chelating agents, in particular metal chelating agents naving specificity for the Ca2+ and Mg2+ ions, such as 1 ,2-diaminocyclohexane- N,N,N',N'-tetraacetic acid (CDTA), diethylenetriamine-pentaacetic acid (DTPA) and ethylenediaminetetraacetic acid (EDTA).
A synergistic effect between the cationic phthalocyanine photosensitizers previously described by the Applicant and metal chelating agents has been observed. In fact, the efficacy of the cationic phthalocynine photosensitizers described in the previous patents and patent applications in the name of the Applicant, when used in combination with metal chelating agents, appears to be advantageously increased not only in comparison with a number of test photosentizers previously described, such as PPC (reported by A. Minnock et al. in J. Photochem. Photobiol. (1996) 32: 159-164) and T4MPyP (reported by M.Merchat et al. in J. Photochem. Photobiol. (1996) 32: 153-157), but also in comparison with the cationic phthalocyanines themselves, tested in the same experimental conditions.
Subject of the present invention are therefore the pharmaceutical compositions comprising at least a metal phthalocyanine analogue of formula (I)
Figure imgf000005_0001
wherein n is O, 1 or 2;
M is chosen in the; group consisting of Zn, Si(OR3)2 and AIOR3 wherein R3 is chosen in the group, consisting of H and Cι.ι5alkyl; R is chosen from H and W, wherein W is represented by the group (X)PR4, wherein:
X is preferably chosen in the group consisting of O, S, -NR and -CH2-; and R is
Figure imgf000005_0002
where :
Y is chosen in the group consisting of C O alkyl and phenyl, possibly substituted, or it forms with the Z group, to which it is bound, a saturated or unsaturated heterocycle, possibly substituted, which may contain up to two heteroatoms chosen in the group consisting of N, O and S; Z is chosen in the group consisting of -N, -CH2N and -CONHCH2CH2N; R5 and Rε, equal or different from one another, are chosen in the group consisting of Cι.15 alkyl and phenyl, or form with the Z group, to which they are bound, a saturated or unsaturated heterocycle, possibly substituted, which may contain up to two heteroatoms chosen in the group consisting of N, O and S; R and R8, equal or different from one another, are chosen in the group consisting of H and Cι.15 alkyl ; m, n, p, s, t and u, independently from one another, are 0 or 1 ; and v is an integer comprised between 1 and 3;
Ri and R2, same or different from each other, are chosen from H, W and K, wherein W is as defined above, and K is selected from the group consisting of -
COOH, -SH, -OH, -NH2, -COCH2Br, S02CI, maleimide, hydrazide, phenol, imidate, and biotine, bound to the phthalocyanine nucleus, possibly through a suitable linker; with the proviso that: when n = 0:. a) Ri = R2 = W in the position 1 ,4 or 2,3; or . b) Ri = H and R2 = W in the position 1 or 2; or c) Ri = H and R2 = K in the position 1 or 2; when n =1: "ti) Ri = H, and R = R2 = W; or
Figure imgf000006_0001
in both cases d) and e) R is in the positions 8(11), 15(18), 22(25), or 9(10), 16(17),
23(24); and R2 is in the position 1(4) or 2(3); when n = 2:
Figure imgf000006_0002
g) R, = H, R = W and R2 = K; in both cases f) and g) R is in the positions 8,11 ,15,18,22,25, or 9,10,16,17,23,24; and in the case f) R-i and R2 are in the positions 1,4 or 2,3; whereas in the case g)
R2 is in the position 1(4) or 2(3); in combination with at least a metal chelating agent.
Further subject of the invention is the use of the present pharmaceutical compositions in photodynamic therapy. Features and advantages of the present formulations will be illustrated in detail in the following description.
Brief description of the drawings
In the Figures described below the data obtained after irradiation of the cell suspensions, previously incubated with the present formulations, with 100 mW/cm2 of red light, are indicated in the histograms by the white rectangles; the data obtained under the same conditions, but without the irradiation of light, are indicated by the dark rectangles.
Figure 1 shows the variation of CFU (colony forming units) of E. co// ATCC 25922 (Log CFU) vs. concentration (μM) of the compound {2,3,9,10,16,17,23,24-octa[3-
(Λ/,Λ/,Λ/-trimethylammonιum)phenoxy] zinc(ll) phthalocyanine} octaiodide
(hereinafter referred to as "compound 1"), when a population of 6.6x106 CFU in
100 μL is incubated for 5 minutes with the above said compound.
Figure 2 shows the variation of CFU of E. coli ATCC 25922 (Log CFU) vs. concentration (μM) of the formulation according to the invention comprising the compound 1 in combination with EDTA 0.5 mM, when a population of 1.0x107 CFU in 100 μL is incubated for 5 minutes with the above said formulation.
Figure 2a shows the variation of CFU of E. coli ATCC 25922 (Log CFU) vs. concentration (μM) of the formulation according to the invention comprising the compound 1 in combination with CDTA 0.5 μM, when a population of 6.6x106 CFU in 100 μL is incubated for 5 minutes with the above said formulation.
Figure 2b shows the variation of CFU of E. coli ATCC 25922 (Log CFU) vs. concentration (μM) of the formulation according to the invention comprising the compound 1 in combination with DTPA 0.5 mM, when a population of 3.3x106 CFU in 100 μL is incubated for 5 minutes with the above said formulation.
Figure 3 shows the variation of CFU of Pseudomonas aeruginosa PAO-1 (Log
CFU) vs. concentration (μM) of the present compound 1 , when a population of
1.3x107 CFU in 100 μL is incubated for 5 minutes with the above said compound.
Figure 3a shows the variation of CFU of P. aeruginosa PAO-1 (Log CFU) vs. concentration (μM) of the present formulation comprising the compound 1 in combination with EDTA 0.5 mM, when a population of 6.6x106 CFU in 100 μL is incubated for 5 minutes with the above said formulation.
Figure 3b shows the variation of CFU of P. aeruginosa PAO-1 (Log CFU) vs. concentration (μM) of the formulation of the invention comprising the compound 1 in combination with CDTA 0.5 mM, when a population of 6.6x106 CFU in 100 μL is incubated for 5 minutes with the above said formulation.
Figure 3c shows the variation of CFU of P. aeruginosa PAO-1 (Log CFU) vs. concentration (μM) of the present formulation comprising the compound 1 in combination with DTPA 0.5 mM, when a population of 6.6x106 CFU in 100 μL is incubated for 5 minutes with the above said formulation.
Figure 4 shows the variation of CFU of P. aeruginosa PAO-1 (Log CFU) vs. concentration (μM) of the present formulation comprising the compound 1 in combination with EDTA 0.5 mM, at different irradiation times with 50 mW/cm2 of red light, when a population of 1.0x107 CFU in 100 μL is incubated with the above said formulation.
Figure 5 shows the variation of CFU of E. coli ATCC 25922 (Log CFU) vs. concentration (μM) of the present formulation comprising the compound
{2(3),9(10),16(17),23(24)-tetra[1 ,3-ib/s-(trimethylammonium)propyl-2-oxy] zinc(ll) hthalocyanine} octaiodide (hereinafter referred to as "compound 2") in combination with EDTA 0.5 mM, when a population of 6.6x106 CFU in 100 μL is incubated for 5 minutes with the above said formulation.
Figure 5a shows the variation of CFU of E. coli ATCC 25922 (Log CFU) vs. concentration (μM) of the present formulation comprising the compound 2, when a population of 1.0x107 CFU in 100 μL is incubated for 5 minutes with the above said formulation.
Figure 6 shows the variation of CFU of P. aeruginosa PAO-1 (Log CFU) vs. concentration (μM) of a formulation comprising the compound 1 in combination with polymixine B sulphate 50 mM, at different irradiation times with 50 mW/cm2 of red light, when a population of 1.0x107 CFU in 100 μL is incubated for 5 minutes with the above said formulation.
Detailed description of the invention The present invention allows to provide novel pharmaceutical compositions directed to the inactivation of Gram negative bacteria with enhanced physical- chemical and photodynamic properties thanks to the combination of the metal phthalocyanine analogues of formula (I) as above defined with at least a metal chelating agent.
According to the present invention Zn(ll) and Si(IV) phthalocyanines are preferred. According to the invention, the definition "suitable linker" is intended in the sense commonly given to this definition in the field of protein and nucleic acid modification (S.S. Wang, Chemistry of Protein Conjugation and Cross-linking CRC Press Inc. 1993, G.T. Hermanson Bioconjugate Techniques Academic Press, 1996), i.e. an aliphatic moiety which acts as a spacer between the phthalocyanine nucleus and the biological macromolecules, in order to satisfy the desired sterical and/or structural requirements. By saturated or unsaturated heterocycle possibly substituted, according to the present invention, the following are preferably meant : morpholine, piperidine, pyridine, pyrimidine, piperazine, pyrrolidine, pyrroline, imidazole, aniline, and julolidine (2,3,6,7-tetrahydro-1H,5H-pyrido[3,2,1-//]quinoline). According to the invention, the preferred products are those in which the group (X)PR includes substituents bearing tertiary or quaternary nitrogen. In particular, the said group (X)PR4, is preferably represented by:
Figure imgf000009_0001
Figure imgf000010_0001
Figure imgf000010_0002
ά ) — CONHCH2CH2N+(CH3)3 I
Figure imgf000010_0003
Figure imgf000011_0001
Figure imgf000011_0002
-N(CH3)2
■ N(C2H5)2 ,N+CH3(C2H5)2 1
Figure imgf000011_0003
,CH3 CH3
— N. — N CH3 H3 CH3
Figure imgf000011_0004
Figure imgf000011_0005
More preferably, the metal phthalocyanine analogues to be used in combination with metal chelating agents in the pharmaceutical compositions of the invention are defined by the following formulas:
{2,3,9,10,16, 17,23,24-octa[3-(Λ/,Λ/,Λ/-trimethylammonium)phenoxy] zinc(ll) phthalocyanine} octaiodide (compound 1 );
{2(3),9(10),16(17),23(24)-tetra[1 ,3-ib/s-(trimethylammonium)propyl-2-oxy] zinc(ll) phthalocyanine} octaiodide (compound 2);
2(3),9(10),16(17),23(24μetra[1 ,3-b/"s-(dimethylamino)propyl-2-oxy] zinc(ll) phthalocyanine (compound 3); {2(3),9(10),16(17),23(24)-tetra[3-(Λ/,/V,Λ/-trimethylammonium)phenoxy] zinc(ll) phthalocyanine} tetraiodide (compound 4);
{2(3),9(10),16(17),23(24)-tetra[3-(Λ/,Λ/,/V-diethylmethylammonium)phenoxy] zinc(ll) phthalocyanine} tetraiodide (compound 5);
{1(4),8(11 ),15(18),22(25)-tetra[3-(Λ/,Λ/,Λ/-trimethylammonium)phenoxy] zinc(ll) phthalocyanine} tetraiodide (compound 6);
{1(4),8(11 ),15(18),22(25)-tetra[3-(Λ/,Λ/,Λ/-diethylmethylammonium)phenoxy] zinc(ll) phthalocyanine} tetraiodide (compound 7);
{2,3,9, 10,16, 17,23,24-octa[3-(Λ/,Λ/,Λ/-diethylmethylammonium)phenoxy] zinc(ll) phthalocyanine} octaiodide (compound 8); 2(3),9(10),16(17),23(24)-tetra[4-(1-methylpiperidinil)oxy] zinc(ll) phthalocyanine
(compound 9);
1 (4),8(11 ),15(18),22(25)-tetra[4-(1-methylpiperidinil)oxy] zinc(ll) phthalocyanine
(compound 10);
2(3),9(10),16(17),23(24)-tetra[2-(piperidin-1 -yl)ethoxy] zinc(ll) phthalocyanine (compound 11);
2(3),9(10),16(17),23(24)-tetra[2-(morpholin-4-yl)ethoxy] zinc(ll) phthalocyanine
(compound 12);
1 (4),8(11 ),15(18),22(25)-tetra[2-(piperidin-1 -yl)ethoxy] zinc(ll) phthalocyanine
(compound 13); 1 ,4,8,11 ,15, 18,22,25-octa[2-(morpholin-4-yl)ethoxy] zinc(ll) phthalocyanine
(compound 14); 1 ,4,8,11 ,15,18,22,25-octa[3-(piperidin-1-yl)propoxy] zinc(ll) phthalocyanine
(compound 15);
1 (4),8(11 ),15(18),22(25)-tetra[2-(morpholin-4-yl)ethoxy] zinc(ll) phthalocyanine
(compound 16); 1 (4),8(11 ),15(18),22(25)-tetra[(T-methylpiperidin-2-yl)methoxy] zinc(ll)phthalocyanine (compound 17);
{2(3),9(10),16(17),23(24)-tetra[N-(2-aminoethyl)benzamidoyl-4-oxy] zinc(ll) phthalocyanine} tetra(trifluoroacetate) (compound 18);
{2(3),9(10),16(17),2,3(24)-tetra[2-(4-methylmorpholin-4-ium)ethoxy] zinc(ll) phthalocyanine} tetraiodide (compound 19);
{2(3),9(10), 16(17),23(24)-tetra[2-(1 -methylpiperidin-1 -ium)ethoxy] zinc(ll) phthalocyanine} tetraiodide (compound 20);
{ 1 (4),8(11 ),15(18),22(25)-tetra[2-(1 -methylpiperidin-1 -ium)ethoxy] zinc(ll) phthalocyanine} tetraiodide (compound 21); {1 (4),8(11 ),15(18),22(25)-tetra[2-(4-methylmorpholin-4-ium)ethoxy] zinc(ll) phthalocyanine} tetraiodide (compound 22);
{2(3),9(10),16(17),23(24)-tetra[4-(1-dimethylpiperidin-1-ium)oxy] zinc(ll) phthalocyanine} tetraiodide (compound 23);
{2(3),9(10),16(17),23(24)-tetra[3-(Λ/,Λ/,Λ/-triethylmethylammonium)phenoxy] zinc(ll) phthalocyanine} tetraiodide (compound 24);
{2(3),9(10),16(17),23(24)-tetra[(Λ/-methyl-2,3,6,7-tetrahydro-1H,5H-pyrido[3,2,1-/ j quinolinium-8-yl)oxy)] phthalocyanine} zinc(ll) iodide (compound 25);
2,3,9,10,16,17,23,24-tetra[(Λ/,Λ/'-dimethyl)piperazo] zinc(ll) phthalocyanine
(compound 26); 2,3,9, 10,16, 17,23,24-octa[2-(/V,/V-diethylamino)ethylthio] zinc(ll) phthalocyanine
(compound 27);
{2,3,9,10,16,17,23,24-octa[3-(/V,Λ/,Λ/-trimethylammonium)phenoxy]-dihydroxy
Si(IV) phthalocyanine} octaiodide (compound 28);
{2,3,9,10,16,17,23,24-tetra[(Λ/,Λ/,Λ/',Λ/'-tetramethyl)piperazinediium] zinc(ll) phthalocyanine} octaiodide (compound 29); {2,3,9,10,16,17,23,24-octa[3-(Λ/,Λ/,Λ/-trimethylammonium)phenylthio] zinc(ll) phthalocyanine} octaiodide (compound 30);
{2,3,9,10,16,17,23,24-octa[3-(1-methylpiridin-ium)oxy] zinc(ll) phthalocyanine} octaiodide (compound 31); 2,3,9, 10,16, 17,23,24-octa[2-(Λ/,Λ/-dimethylamino)ethylthio] zinc(ll) phthalocyanine (compound 32);
{2,3,9,10,16,17,23,24-octa[2-(Λ/,/V,Λ/-trimethylammonium)ethylthio] zinc(ll) phthalocyanine} octaiodide (compound 33). Pharmaceutically acceptable salts of the phthalocyanine compounds of the present invention, bearing basic substituents, include conventional acid addition salts, obtained by the addition of HCI, H3PO4, H2S04, HBr, etc. Additionally, salts obtained by reaction of the carboxylic function or acid groups within the phthalocyanine ring are within the scope of the present invention. Such salts include, for example, salts of carboxylic and sulfonic acid with amine derivatives, basic amino acids and inorganic bases.
The phthalocyanine compounds of the present invention can be prepared according to reaction schemes that are known in organic chemistry. The present compounds of formula (I) included in the cases d) and f) may be prepared as described in US Patent No. 5,965,598, which we incorporate herewith by reference; whereas the present compounds of formula (I) included in cases c), e) and g) may be prepared as described in the International Patent Application No. PCT/EP02/03108, which we incorporate herewith by reference; the present compounds of formula (I) of cases a) and b) may be prepared as described in the European Patent Application No. EP 00112654.9, which we incorporate herewith by reference.
The phthalocyanine compounds indicated above as compounds 1-24 have been already disclosed in the above said Patent Applications, whereas the compounds indicated above as compounds 25-33 have been newly prepared as described in the following examples. The present compositions comprise at least a metal chelating agent, preferably selected from the metal chelating agents having specificity for the Ca2+ and Mg2+ ions, such as 1 ,2-diaminocyclohexane-N,N,N',N'-tetraacetic acid (CDTA), diethylenetriamine-pentaacetic acid (DTPA), ethylenediamine-N,N,N',N'-tetraacetic acid (EDTA), and salts thereof.
More preferred compositions according to the invention are those comprising
EDTA. Photodynamic therapy using the phthalocyanine compounds formulated with the compound described in the present invention has a number of advantages. The phthalocyanine compounds themselves are minimally toxic in the unexcited state. Each phthalocyanine molecule can be repeatedly photoactivated and leads each time to cell-lethal events, that are the generation of singlet molecular oxygen or radicals. The half-life of singlet oxygen is such that the target cell is affected without the opportunity for migration of the lethal singlet oxygen to neighbouring healthy tissue cells. Singlet oxygen molecules target microorganism cell wall, or destroy intracellular structures, resulting in destruction of the target cell, without affecting chemical bonds in the cell DNA, at least at the doses which provide a complete photoinactivation. Destruction of target cell tissue commences promptly upon irradiation of the phthalocyanine compounds and ceases abruptly when irradiation is stopped and, due to the non interference with DNA, a development of resistance in microorganisms is unlikely. Photodynamic therapy with the compounds of the present invention is therefore selective and minimally toxic to healthy tissues. The produced singlet oxygen molecules that do not react rapidly with neighbouring molecules rapidly decay.
A variety of phototherapy and irradiation methodologies are known to those skilled in the art and can be used with the phthalocyanine metal chelating derivatives of the present invention. The time and duration of therapy and repetition of the irradiation treatment can be selected by the physician, according to known photodynamic therapy criteria. The dosage of the phthalocyanine and the metal chelating compound in the present compositions may be varied, according to the size and location of the target tissues which are to be destroyed and the method of administration. Generally, in the case of systemic (e.g. intravenous) administration of the photosensitizer, the dosage will be in the range between 0.1 and 20 mg of phthalocyanine compound per kilogram of body weight per day, more preferably in the range between 0.1 and 5.0 mg/kg. In the case of tdpical'deposition of the photosensitizer, the phthalocynine dosage will be in the range between 0.1 and 100 μg of compound per cm2 of tissue, more preferably in the range between 1 and 10 μg/cm2.
The metal chelating compounds of the present invention may be administered in an amount ranging between 0.01 and 100 mg of the chelating compound per kilogram of body weight per day, and preferably in an amount ranging from 0.1 to 10 mg/Kg per day, in case of systemic administration, while a dosage between 0.1 and 100 μg/cm2 per day, preferably in an amount ranging from 1 to 20 μg/cm2, will be used in case of topical deposition. For the treatment of infectious diseases, irradiation generally takes place not more than four days after systemic administration of the phthalocyanine compound. Usually, phototherapy begins approximately 10 hours to 24 hours after systemic administration of the photodynamic therapy agent. For dermatological infectious diseases, radiation therapy can commence immediately after topical application of the phthalocyanine or at any desired time up to 24 hours later. Systemic application for treatment of dermatological diseases is followed by radiation usually 15 to 24 hours after systemic administration of the PDT agent. Exposure to non therapeutic light sources should be avoided immediately following phototherapy, to minimize light toxicity. Appropriate protection of the patient can be used, to limit the area affected by phototherapy.
Light sources suitable for the use in PDT are well known in the art and may vary from white light sources associated with appropriate filters to lasers tuned to the right wavelength. As noted above, preferred wavelengths are from 600 to 950 nm, preferably from about 650 to about 750 nm. The total amount of light which is applied to the affected area will vary with the treatment method used and with the location of the lesion. Generally, the amount of light is in the range of about 50 to 1000 J cm"2, preferably in the range of 100 to 350 J cm"2.
The present pharmaceutical compositions show valuable photodynamic characteristics and higher than the photosensitising agents previously described; these properties make them useful in photodynamic therapy (PDT) against bacterial, fungal and viral infections, in particular against Gram negative bacteria; as well as for sterilization of blood and blood derivatives, such as platelets and erythrocytes. In this case, the present compositions can be added directly to blood or blood derivatives, or previously bound to suitable matrix, according to known techniques and, thereafter, irradiated.
EXAMPLE 1 {2(3),9(10),16(17),23(24)-tetra[(Λ/-methyl-2,3,6,7-tetrahydro-1H,5H-pyrido[3,2,1-/7J quinolinium-8-yl)oxy)] phthalocyanine} zinc(.ll) iodide (compound 25) blue-green powder; formula: C84H80l4N12O4Zn; UV-Vis (DMF) λmaχ (nm) 678 (ε -
174000 M-1 cm-1), 610, 357; 1H-NMR (200 MHz, DMSO-d6) δ = 9.50-9.38 (m, 4H),
9.20-8.95 (m, 4H), 7,95-7.82 (m, 4H), 7.46-7.42 (m, 8H), 4.10-3.91 (m, 16H), 3.55 (s, 12H), 3.30-3.20 (m, 16H), 2.72-2.60 (m, 8H), 2.40-2.30 (m, 8H); 13C-NMR (75
MHz, DMSO- 6) δ 159.05, 158.94, 153.61 , 153.48, 140.56, 134.25, 134.09,
130.06, 126.82, 126.76, 125.33, 123.35, 122.42, 120.87, 111.97, 111.75, 63.14,
62.71 , 51.60, 23.84, 19.53, 16.07, 15.49; ESI-MS m/z 346 [(M -4I)4+], 457 [(M -4I -
CH3)3+], 678 [(M -4I - 2CH3)2+], 1342 [(M -4I -3CH3)+]. EXAMPLE 2
2,3,9,10,16,17,23,24-tetra[(Λ/,Λ/'-dimethyl)piperazo] zinc(ll) phthalocyanine
(compound 26) blue-green powder; formula: C 8H48N16Zn; UV-Vis (DMF) λmaχ (nm) 722; 1H-NMR
(200 MHz, DMSO- 6) δ = 8.37 (s, 8H), 3.69 (s, 16H), 3.43 (s, 24H); FAB-MS m/z 912 [M+].
EXAMPLE 3
2,3,9,10,16,17,23,24-octa[2-(Λ/,Λ/-diethylamino)ethylthio] zinc(ll) phthalocyanine
(compound 27) blue-green powder; formula: C88H12oNι6S8Zn. EXAMPLE 4
{2,3,9,10,16,17,23,24-octa[3-(Λ/,Λ/,Λ/-trimethylammonium)phenoxy]-dihydroxy
Si(IV) phthalocyanine} octaiodide (compound 28) blue-green powder; formula: C104Hι14l8N16OιoSi; UV-Vis (DMF) λmax (nm) 677,
609, 364; 1H-NMR (200 MHz, DMSO- 6) δ = 9.44 (s, 8H), 8.03 (bs, 8H), 7.85-7.65 (m, 16H), 7.50-7.40 (m, 8H), 3.68 (s, 72H); ESI-MS m/z 223 [(M -8I)8+], 429 [(M -8I
- 4CH3)4+], 567 [(M -8I - 5CH3)3+], 843 [(M -8I -6CH3)2+], 1671 [(M -8I -7CH3)+]. EXAMPLE 5 .
{2,3,9,10,16,17,23,24-tetra[(Λ/,/V,Λ/ Λ/'-tetramethyl)piperazinediium] zinc(ll) phthalocyanine} octaiodide (compound 29) blue-green powder; formula: C56H72l8N16Zn; UV-Vis (DMF) λmax (nm) 722, 650, 372.
EXAMPLE 6
{2,3,9,10,16,17,23,24-octa[3-(Λ/,Λ/,Λ/-trimethylammonium)phenylthio] zinc(ll) phthalocyanine} octaiodide (compound 30) blue-green powder; formula: C104H11 l8N16S8Zn; UV-Vis (DMF) λmaχ (nm) 707 (ε = 146000 M-1 cm-1), 385, 635; 1H-NMR (200 MHz, DMSO-d6) δ = 9.46 (s, 8H), 8.31
(bs, 8H), 8.02-7.98 (m, 8H), 7.70 (dd, 8H, J = 8.0 Hz), 7.57-7.54 (m, 8H), 3.71 (s,
72H).
EXAMPLE 7
{2,3,9,10,16,17,23,24-octa[3-(1-methylpiridin-ium)oxy] zinc(ll) phthalocyanine} octaiodide (compound 31) blue-green powder; formula: C8oH64l8Nι6O8Zn; UV-Vis (DMF) λmax (nm) 675; 1H-
NMR (300 MHz, DMSO-d6) δ = 9.56 (s, 8H), 9.33 (s, 8H), 8.93-8.91 (m, 8H) ,
8.67-8.64 (m, 8H), 8.27-8.22 (m, 8H), 4.40 (s, 24H); 13C-NMR (75 MHz, DMSO-d6>
^elected data) δ = 156.66, 153.35, 147.58, 142.06, 137.34, 136.80, 133.93, 129.74, 49.17.
EXAMPLE 8
2,3,9,10,16,17,23,24-octa[2-(Λ/,Λ/-dimethylamino)ethylthio] zinc(ll) phthalocyanine
(compound 32) blue-green powder; formula: C72H88Ni6S8Zn. EXAMPLE 9
12,3,9,10,16,17,23,24-octa[2-(A/,A/,A/-trimethylammonium)ethylthio] zinc(ll) phthalocyanine} octaiodide (compound 33) blue-green powder; formula: C80Hι12l8N16S8Zn; UV-Vis (DMF) λmax (nm) 703, 631 ,
386; 1H-NMR (300 MHz, DMSO-d6) δ = 9.50 (s, 8H), 4.15-4.00 (m, 16H) , 3.90- 3.80 (m, 16H), 3.40 (s, 72H); 13C-NMR (75 MHz, DMSO-d6) selected data) δ =
153.7, 137.8, 137.1 , 123.7, 64.1 , 53.3, 26.9. BIOCIDAL ACTIVITY
The usefulness of the pharmaceutical compositions of the present invention has been evaluated through their activity against the Gram negative micro-organisms Pseudomonas aeruginosa PAO-1 and E. coli ATCC 25922. These microorganisms were used in the experiments in a stationary phase of growth. The experimental protocol was the following:
The cell suspensions were diluted in an appropriate medium. Addition of an aliquot of stock solution of the composition to be tested to the cell suspension up to the intended final concentrations. Incubation in dark at 37 °C for 5 minutes. Irradiation (650 < λ < 850 nm; 50 ÷100 mW/cm2; 1 ÷ 10 minutes) of cell suspension for each dilution of the photosensitising composition.
Figure 1 shows the photoinactivation of E. coli as a function of the concentration of the compound {2,3,9,10,16,17,23, 24-octa[3-(Λ/,Λ/,Λ/-trimethylammonium)phenoxy] zinc(ll) phthalocyanine} octaiodide (compound 1). Compound 1 can afford a 4 log reduction of the initial population, but a complete sterilization of the cell suspension cannot De obtained.
The photoinactivation of E. coli caused by the compound 1 in combination with 0.5 mM of EDTA has been observed; as it can be seen in Figure 2, the compound 1 in the presence of EDTA is able to sterilize completely the cell suspension at concentrations as low as 1 μM.
Similar results can be also obtained by using CDTA or DTPA 0.5 mM (see Figures 2a and 2b).
Even more dramatic results can be obtained for the inactivation of Pseudomonas aeruginosa, a microorganism which is most refractory and difficult to inactivate. In this case, compound 1 is not active up to 40 μM concentration (see Figure 3), while by using EDTA, a concentration of 1 μM reduces the population by 5 log and a 5 μM concentration is able to sterilize the cell suspension (see Figure 3a). Also in this case, similar results can be obtained with CDTA and DTPA (see Figures 3b and 3c). It is worth noting that the inactivation can be performed by using lower fluence rates of light (50 mW/cm2) and only 1 minute of irradiation (0.3 Jem"2) with 5 μM concentration is able to reduce the initial population by 4.5 log (see Figure 4). Another example is provided by the use of the compound {2(3),9(10),16(17),23(24)-tetra[1 ,3-jb/s-(trimethylammonium)propyl-2-oxy] zinc(ll) phthalocyanine} octaiodide (compound 2) against E. coli with and without EDTA (see respectively Figure 5 and 5a). It is clearly shown that the presence of EDTA enables the reduction of the photosensitizer concentration necessary to sterilize the cell suspension from 20 μM to 1 μM.
The synergistic effect of the present compositions is evident from the Figure 6, wherein the results of a comparison experiment have been reported; in this experiment a phthalocyanine of formula (I) is used in combination with an enhancer commonly used, polymixine B sulphate, thus obtaining a scarce photoinactivation of the microorganisms, even at a concentration of 5 μM. PHARMACEUTICAL FORMULATIONS
Compositions as previously described may be administered by various routes, including parenteral or topical administration. In particular, the present compositions can be used either for topical treatment of skin or mucosae diseases, as well as for the ex vivo treatments, such as blood or blood derivatives sterilization.
Pharmaceutical compositions according to the present invention include solutions, Jjposome or microvesicle preparations, dispersions, ointments and other suitable topical dermatological preparations, or preparations suitable for ex vivo applications.
Such compositions may comprise pharmacologically acceptable diluents or excipients. Parenteral Solutions The photoactivatable phthalocyanines are generally used with additional solvents and adjuvants, to prepare solutions suitable for the in vivo or ex vivo administration. A number of solvents and co-solvents, that are miscible with water and suitable surfactants, can be used to achieve solutions for ex vivo application, assimilated to parenteral solutions and formulations. The most important solvents in this group are ethanol, polyethylene glycols of the liquid series and propylene glycol. A more comprehensive listing includes dimethyl sulfoxide, ethanol, glycerin, polyethylene glycol 300 and 400, propylene glycol, sorbitol, polyoxyethylene sorbitan, fatty acid esters such as laurate, palmitate, stearate and oleate, polyoxyethylated vegetable oil, sorbitan monopalmitate, 2-pyrrolidpne, N-methyl-2- pyrrolidine, N-ethyl-2-pyrrolidine and tetrahydrofurfuryl alcohol. Other additives may be necessary to enhance or maintain chemical stability and physiological suitability. Examples are antidxidants, chelating agents, inert gases, buffers and isotonicifiers. Topical Formulations
The phthalocyanine and enhancers compounds of the present invention may be formulated for topical application in penetrating solvents or in the form of a lotion, cream, ointment or gel, containing a sufficient amount of the phthalocyanine compound to be effective for PDT.
Suitable penetrating solvents are those which will enhance percutaneous penetration of the phthalocyanine compound. Solvents having this property include dimethyl sulfoxide, 1-methyl-2-pyrrolidone, Azone®, Transcutol®, lauric acid and esters, essential oils, propylene glycol, ethanol and PEG at various molecular weights. DMSO solutions containing 0-50 wt. % of water are particularly desirable. Liposome or Micrόvesicle Preparations
Liposomes are microvesicles which encapsulate a liquid within lipid or polymeric membranes; the methods of preparing liposomes for both topical and parenteral (injectable) preparations are known in the art and can be used for the purposes of the present invention. The present compositions having overall lipophilic characteristics may be incorporated into liposome microvesicles and used in this form for both topical and ex vivo applications.

Claims

1. Pharmaceutical compositions comprising at least a metal phthalocyanine analogue of formula (I)
Figure imgf000022_0001
wherein n is 0, 1 or 2;
M is chosen in the group consisting of Zn, Si(OR3)2 and AIOR3 wherein R3 is chosen in the group consisting of H and C-1.15 alkyl; R is chosen from H and W, wherein W is represented by the group (X)PR4, wherein: ;X is preferably chosen in the group consisting of O, S, -NR7 and -CH2-;
Figure imgf000022_0002
where :
Y is chosen in the group consisting of C-MO alkyl and phenyl, possibly substituted, or it forms with the Z group,, to which it is bound, a saturated or unsaturated heterocycle, possibly substituted, which may contain up to two heteroatoms chosen in the group consisting of N, O and S; Z is chosen in the group consisting of -N, -CH2N and -CONHCH2CH2N; » R5 and R6, equal or different from one another, are chosen in the group consisting of C1-15 alkyl and phenyl, or form with the Z group, to which they are bound, a saturated or unsaturated heterocycle, possibly substituted, which may contain up to two heteroatoms chosen in the group consisting of N, O and S;
R7 and R8, equal or different from one another, are chosen in the group consisting of H and CMS alkyl ; m, n, p, s, t and u, independently from one another, are 0 or 1 ; and v is an integer comprised between 1 and 3; Ri and R2, same or different from each other, are chosen from H, W and K, wherein W is as defined above, and K is selected from the group consisting of -
COOH, -SH, -OH, -NH2, -COCH2Br, SO2CI, maleimide, hydrazide, phenol, imidate, and biotine, bound tg the phthalocyanine nucleus, possibly through a suitable linker; with the proviso that: when n = 0: a) Ri = R2 = W in the position 1 ,4 or 2,3; or b) Ri = H and R2 = W in the position 1 or 2; or c) Ri = H and R2 = K in the position 1 or 2; when n =1 : d) Ri = H, and R = R2 = W; or e) R1 = H, R = W and R2 = K; in both cases d) and e) R is in the positions 8(11), 15(18), 22(25), or 9(10), 16(17), 23(24); and R2 is in the position 1(4) or 2(3); when n = 2:
Figure imgf000023_0001
g) , = H, R = W and R2 = K; in both cases f) and g) R is in the positions 8,11 ,15,18,22,25, or 9,10,16,17,23,24; and in the case f) R-i and R2 are in the positions 1 ,4 or 2,3; whereas in the case g) R2 is in the position 1 (4) or 2(3); in combination with at least a metal chelating agent.
2. The pharmaceutical compositions according to claim 1 , wherein M is Zn or Si(OR3)2, where R3 is defined as above in claim 1.
3. The pharmaceutical compositions according to claim 1 , wherein the group (X)PR2 is chosen in the group consisting of:
Figure imgf000024_0001
Figure imgf000025_0001
Figure imgf000025_0002
A— CONHCH2CH2NH2 I '
Figure imgf000025_0003
Figure imgf000026_0001
Figure imgf000026_0002
ι
-N(CH3)2
^^ C2Ηs N+CH3(C2H5)2 I
Figure imgf000026_0003
,CH3
— N. N-CH3 CH3 CH3
Figure imgf000026_0004
Figure imgf000026_0005
>5
4. The pharmaceutical composition according to claim 1 , wherein the said metal phthalocyanine analogue is defined by the following formulas:
{2,3,9,10,16,17,23,24-octa[3-(Λ/,Λ/,Λ/-trimethylammonium)phenoxy] zinc(ll) phthalocyanine} octaiodide (compound 1); {2(3),9(10),16(17),23(24)-tetra[1 ,3-b/'s-(trimethylammonium)propyl-2-oxy] zinc(ll) phthalocyanine} octaiodide (compound 2); .
2(3),9(10),16(17),23(24)-tetra[1 ,3-/?/'s-(dimethylamino)propyl-2-oxy] zinc(ll) phthalocyanine (compound 3);
{2(3),9(10),16(17),2β(24)-tetra[3-(Λ/,Λ/,Λ/-trimethylammonium)phenoxy] zinc(ll) phthalocyanine} tetraiodide (compound 4);
{2(3),9(10),16(17),23(24)-tetra[3-(Λ/,Λ/,Λ/-diethylmethylammonium)phenoxy] zinc(ll) phthalocyanine} tetraiodide (compound 5);
{ 1 (4),8(11 ),15(18),22(25)-tetra[3-(Λ/,Λ/,Λ/-trimethylammonium)phenoxy] zinc(ll) phthalocyanine} tetraiodide (compound 6); {1 (4),8(11 ),15(18),22(25)-tetra[3-(Λ/,Λ/,Λ/-diethylmethylammonium)phenoxy] zinc(ll) phthalocyanine} tetraiodide (compound 7);
{2,3,9,10,16,17,23,24-octa[3-(Λ/,Λ/,Λ/-diethylmethylammonium)phenoxy] zinc(ll) phthalocyanine} octaiodide (compound 8);
2(3),9(10),16(17),23(24)-tetra[4-(1 -methylpiperidinil)oxy] zinc(ll) phthalocyanine (compound 9);
1 (4),8(11 ),15(18),22(25)-tetra[4-(1 -methylpiperidinil)oxy] zinc(ll) phthalocyanine
(compound 10);
2(3),9(10),16(17),23(24)-tetra[2-(piperidin-1-yl)ethoxy] zinc(ll) phthalocyanine
(compound 11); . 2(3),9(10),16(17),23(24)-tetra[2-(morpholin-4-yl)ethoxy] zinc(ll) phthalocyanine
(compound 12);
1 (4),8(11 ),15(18),22(25)-tetra[2-(piperidin-1 -yl)ethoxy] zinc(ll) phthalocyanine
(compound 13);
1 ,4,8, 11 ,15, 18,22,25-octa[2-(morpholin-4-y!)ethoxy] zinc(ll) phthalocyanine (compound 14); 1 ,4,8,11 ,15,18,22,25-octa[3-(piperidin-1 -yl)propoxy] zinc(ll) phthalocyanine
(compound 15);
1(4),8(11),15(18),22(25)-tetra[2-(morpholin-4-yl)ethoxy] zinc(ll) phthalocyanine
(compound 16); 1(4),8(11),15(18),22(25)-tetra[(1-methylpiperidin-2-yl)methoxy] zinc(ll)phthalocyanine (compound 17);
{2(3),9(10),16(17),23(24)-tetra[N-(2-aminoethyl)benzamidoyl-4-oxy] zinc(ll) phthalocyanine} tetra(trifluoroacetate) (compound 18);
{2(3),9(10),16(17),23(24)-tetra[2-(4-methylmorpholin-4-ium)ethoxy] zinc(ll) phthalocyanine} tetraiodide (compound 19);
{2(3),9(10), 16(17),23(24)-tetra[2-(1 -methylpiperidin-1 -ium)ethoxy] zinc(ll) phthalocyanine} tetraiodide (compound 20);
{1 (4),8(11 ),15(18),22(25)-tetra[2-(1 -methylpiperidin-1 -ium)ethoxy] zinc(ll) phthalocyanine} tetraiodide (compound 21 ); { 1 (4),8(11 ), 5(18),22(25)-tetra[2-(4-methylmorpholin-4-ium)ethoxy] zinc(ll) phthalocyanine} tetraiodide (compound 22);
{2(3),9(10),16(17),23(24)-tetra[4-(1-dimethylpiperidin-1-ium)oxy] zinc(ll) phthalocyanine} tetraiodide (compound 23);
^2(3),9(10),16(17),23(24)-tetra[3-(Λ/,Λ/,Λ/-triethylmethylammonium)phenoxy] zinc(ll) phthalocyanine} tetraiodide (compound 24);
! 2(3),9(10),16(17),23(24)-tetra[(Λ/-methyl-2,3,6,7-tetrahydro-1H,5W-pyrido[3,2,1-/7J quinolinium-8-yl)oxy)j phthalocyanine} zinc(ll) iodide (compound 25);
2,3,9,10,16,17,23,24-tetra[( V,/V'-dimethyl)piperazo] zinc(ll) phthalocyanine
(compound 26); 2,3,9,10,16,17,23,24-octa[2-(Λ/,Λ/-diethylamino)ethylthio] zinc(ll) phthalocyanine
(compound 27);
{2,3,9, 10,16,17,23,24-octa[3-(/V,/V,Λ/-trimethylammonium)phenoxy]-dihydroxy
Si(IV) phthalocyanine} octaiodide (compound 28);
{2,3,9,10,16,17,23,24-tetra[(/V,A/,Λ/',Λ/-tetramethyl)piperazinediium] zinc(ll) phthalocyanine} octaiodide (compound 29); {2,3,9,10,16,17,23,24-octa[3-(Λ/)Λ/,Λ/-trimethylammonium)phenylthio] zinc(ll) phthalocyanine} octaiodide (compound 30);
{2,3,9,10,16,17,23,24-octa[3-(1-methylpiridin-ium)oxy] zinc(ll) phthalocyanine} octaiodide (compound 31); 2,3,9,10,16,17,23,24-octa[2-(Λ/,Λ/-dimethylamino)ethylthio] zinc(ll) phthalocyanine (compound 32);
{2,3,9,10,16,17,23,24-octa[2-(Λ/,Λ/,/\/-trimethylammonium)ethylthio] zinc(ll) phthalocyanine} octaiodide (compound 33).
5. The pharmaceutical compositions according to any of claims 1-4, wherein the said metal chelating agent is selected from the metal chelating agents having specificity for Ca2+ and Mg2+ ions.
6. The pharmaceutical compositions according to claim 5, wherein the said metal chelating agent is selected from 1 ,2-diaminocyclohexane-N,N,N',N'-tetraacetic acid (CDTA), diethylenetriamine-pentaacetic acid (DTPA) and ethylenediamine- N,N,N',N'-tetraacetic, acid (EDTA).
7. The pharmaceutical compositions according to claim 6, wherein the said metal chelating agent is EDTA.
8. The pharmaceutical compositions according to any of claims 1-7, in a formulation selected from solutions, liposome or microvescicle preparations, dispersions, ointments, and other suitable topical dermatological preparations or preparations suitable for ex vivo applications.
9. Use of at least a metal phthalocyanine analogue of formula (I) in combination with at least a metal chelating agent according to claims 1-8, for the preparation of pharmaceutical compositions for the photodynamic therapy.
10. Use according to claim 9, wherein the said photodynamic therapy consists in the topical treatment of skin or mucosas diseases caused by Gram negative bacteria.
11. Use of at least a metal phthalocyanine analogue of formula (I) in combination with at least a metal chelating agent according to claims 1-8, for the preparation of pharmaceutical compositions for blood or blood derivatives sterilisation.
PCT/EP2003/004080 2002-04-25 2003-04-17 Antibacterial compositions comprising metal phthalocyanine analogues WO2003090744A1 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
JP2003587378A JP2005524692A (en) 2002-04-25 2003-04-17 Antimicrobial composition comprising a metal phthalocyanine analog
IL16480103A IL164801A0 (en) 2002-04-25 2003-04-17 Antibacterial compositions comprising metal phthalocyanines analogues
CA2484070A CA2484070C (en) 2002-04-25 2003-04-17 Antibacterial compositions comprising metal phthalocyanine analogues
US10/512,287 US8664382B2 (en) 2002-04-25 2003-04-17 Antibacterial compositions comprising metal phthalocyanine analogues
AU2003224100A AU2003224100B2 (en) 2002-04-25 2003-04-17 Antibacterial compositions comprising metal phthalocyanine analogues
ZA2004/09452A ZA200409452B (en) 2002-04-25 2004-11-23 Antibacterial compositions comprising metal phthalocyanine analogues

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02009414.0 2002-04-25
EP02009414A EP1356813B1 (en) 2002-04-25 2002-04-25 Antibacterial compositions comprising metal phthalocyanine analogues

Publications (2)

Publication Number Publication Date
WO2003090744A1 true WO2003090744A1 (en) 2003-11-06
WO2003090744A8 WO2003090744A8 (en) 2004-03-18

Family

ID=28685904

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2003/004080 WO2003090744A1 (en) 2002-04-25 2003-04-17 Antibacterial compositions comprising metal phthalocyanine analogues

Country Status (14)

Country Link
US (1) US8664382B2 (en)
EP (1) EP1356813B1 (en)
JP (1) JP2005524692A (en)
CN (1) CN1332658C (en)
AT (1) ATE299705T1 (en)
AU (1) AU2003224100B2 (en)
CA (1) CA2484070C (en)
DE (1) DE60205085T2 (en)
DK (1) DK1356813T3 (en)
ES (1) ES2244694T3 (en)
IL (1) IL164801A0 (en)
SI (1) SI1356813T1 (en)
WO (1) WO2003090744A1 (en)
ZA (1) ZA200409452B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210032261A1 (en) * 2018-04-09 2021-02-04 Chemical Intelligence Limited Antimicrobial and anticancer cationic phthalocyanine compounds

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITFI20050093A1 (en) 2005-05-05 2006-11-06 Molteni & C PROCESS FOR THE PREPARATION OF CHLORIDE OF PHYTALOCYANIC DERIVATIVES INCLUDING AT LEAST A AMMONIUM QUATERNARY GROUP
ITFI20050092A1 (en) 2005-05-05 2006-11-06 Molteni & C PHYTALOCIANINE DERIVATIVES, PROCESS FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND THEIR USE
AU2006263834B8 (en) * 2005-06-29 2011-11-17 Molteni Therapeutics S.R.L. Self-sterilizing products
ES2367371T3 (en) * 2005-06-29 2011-11-02 L. MOLTENI &amp; C. DEI FRATELLI ALITTI SOCIETA' DI ESERCIZIO SOCIETA' PER AZIONI USE OF FTALOCIANINE DETERIVED FOR NON-PHOTODYNAMIC TREATMENT OF DISEASES.
PL1904060T3 (en) * 2005-06-29 2011-12-30 Molteni Therapeutics S R L Use of phthalocyanine derivates for the non-photodynamic treatment of diseases
CN102351864A (en) * 2011-07-20 2012-02-15 东北师范大学 Organic-functionalized non-aggregated phthalocyanine and preparation method thereof
CN102702210B (en) * 2012-06-01 2014-09-10 福州大学 Application of phthalocyanine metal complex containing piperazine ethyoxyl modified groups
CN103601728B (en) * 2013-11-25 2015-09-09 吉林大学 Solvable phthalocyanine derivates and for the preparation of organic and polymer solar photovoltaic device in water or water/alcohol
MY164075A (en) * 2014-09-09 2017-11-17 Purepurge Inc Compositions for photodynamic control of infection
CN104610270B (en) * 2015-01-28 2017-03-08 吉林大学 Metal phthalocyanine is the embellishing cathode interface material of core and is used for preparing polymer photovoltaic cell
FI127163B (en) 2016-11-17 2017-12-29 Tty-Säätiö photosensitizer
EP3934691A1 (en) * 2019-03-06 2022-01-12 Molteni Therapeutics S.r.l. Topical formulations containing phthalocyanine photosensitizers
CN111072679B (en) * 2020-01-16 2022-07-01 福州大学 Non-peripheral quaternary ammonium group modified zinc phthalocyanine and preparation method and application thereof
CN112028901B (en) * 2020-10-16 2021-06-01 福州大学 Cetyl ammonium group modified phthalocyanine, preparation method thereof and application thereof as photodynamic medicament

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5135717A (en) * 1986-12-24 1992-08-04 British Technology Group Usa Inc. Tetrabenztriazaporphyrin reagents and kits containing the same
EP0906758A1 (en) * 1997-08-14 1999-04-07 MOLTENI L. &amp; C. dei Fratelli Alitti Società di Esercizio S.P.A. Zinc-phthalocyanines and corresponding conjugates, their preparation and use in photodynamic therapy and as diagnostic agents
EP1164135A1 (en) * 2000-06-15 2001-12-19 L. MOLTENI &amp; C. DEI FRATELLI ALITTI SOCIETA' DI ESERCIZIO SOCIETA' PER AZIONI Substituted metal-phthalocyanines, their preparation and the use thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1007239B (en) * 1986-08-28 1990-03-21 切夫尔昂研究公司 With sequestrant to the hydrocarbon feed process for demetalizating
ATE298341T1 (en) 2001-03-21 2005-07-15 Molteni & C METAL-SUBSTITUTED NON-CENTROSYMMETRIC PHTHALOCYANINE ANALOGS, THEIR PREPARATION AND USE FOR PHOTODYNAMIC THERAPY AND AS IN VIVO DIAGNOSTICS
ITFI20020200A1 (en) 2002-10-21 2004-04-22 Molteni & C Dei Flii Alitti S P A Societa L MESO-REPLACED PORPHYRINES.

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5135717A (en) * 1986-12-24 1992-08-04 British Technology Group Usa Inc. Tetrabenztriazaporphyrin reagents and kits containing the same
EP0906758A1 (en) * 1997-08-14 1999-04-07 MOLTENI L. &amp; C. dei Fratelli Alitti Società di Esercizio S.P.A. Zinc-phthalocyanines and corresponding conjugates, their preparation and use in photodynamic therapy and as diagnostic agents
EP1164135A1 (en) * 2000-06-15 2001-12-19 L. MOLTENI &amp; C. DEI FRATELLI ALITTI SOCIETA' DI ESERCIZIO SOCIETA' PER AZIONI Substituted metal-phthalocyanines, their preparation and the use thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
WÖHRLE D ET AL: "A simple synthesis of 4,5-disubstituted 1,2-dicyanobenzenes and 2,3,9,10,16,17,23,24-octasubstituted phthalocyanines", SYNTHESIS, 1 February 1993 (1993-02-01), pages 194 - 196, XP002090442, ISSN: 0039-7881 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210032261A1 (en) * 2018-04-09 2021-02-04 Chemical Intelligence Limited Antimicrobial and anticancer cationic phthalocyanine compounds

Also Published As

Publication number Publication date
WO2003090744A8 (en) 2004-03-18
SI1356813T1 (en) 2006-02-28
US20050234032A1 (en) 2005-10-20
DK1356813T3 (en) 2005-12-05
ZA200409452B (en) 2005-12-28
EP1356813B1 (en) 2005-07-20
CN1332658C (en) 2007-08-22
ATE299705T1 (en) 2005-08-15
EP1356813A1 (en) 2003-10-29
AU2003224100B2 (en) 2006-10-05
ES2244694T3 (en) 2005-12-16
IL164801A0 (en) 2005-12-18
DE60205085D1 (en) 2005-08-25
CN1649584A (en) 2005-08-03
US8664382B2 (en) 2014-03-04
AU2003224100A1 (en) 2003-11-10
CA2484070C (en) 2011-08-23
CA2484070A1 (en) 2003-11-06
JP2005524692A (en) 2005-08-18
DE60205085T2 (en) 2006-04-20

Similar Documents

Publication Publication Date Title
EP1356813B1 (en) Antibacterial compositions comprising metal phthalocyanine analogues
Mroz et al. Photodynamic therapy with fullerenes
EP1558616B2 (en) Meso-substituted porphyrins
ES2244793T3 (en) NON CENTROSIMETRIC ANALOGS OF PHTALOCIANINE REPLACED BY METALS, ITS PREPARATION AND ITS USE IN PHOTODYNAMIC THERAPY AND IN VIVO DIAGNOSIS.
US6107326A (en) Porphycenes for treatment of microbial populations
EP1164135B1 (en) Substituted metal-phthalocyanines, their preparation and the use thereof
JP5372371B2 (en) Cationic bacteriochlorophyll derivatives and uses thereof
AU2001272463A1 (en) Substituted metal-phthalocyanines, their preparation and the use thereof
AU2002341034A1 (en) Metal substituted non centrosimmetrical phthalocyanine analogues, their preparation and use in photodynamic therapy and in vivo diagnostic
ES2372854B1 (en) CATIÓNIC DERIVATIVES OF 2, 7, 12, 17-ARILPORFICENOS. PROCEDURE FOR PREPARATION AND USE AS PHOTOSENSITIZERS IN ANTIMICROBIAL PHOTODYNAMIC THERAPY.
RU2646477C1 (en) Photosensitiser for treatment of cancer diseases and method of its obtaining
CN118141916A (en) Photosensitive pharmaceutical preparation for photodynamic sterilization and application thereof
EP3983486A1 (en) Small cationic ortho-5,15-di-heteroaryl-porphyrins derivatives and their applications in photoinactivation of microorganisms
Young The Development of a Novel Series of Cationic Porphyrins as Disinfectants for Use in Public Health
JP2002212066A (en) New photochemotherapeutic agent

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: IN PCT GAZETTE 45/2003 UNDER (72, 75) IN THE ADDRESS OF RONCUCCI, GABRIO REPLACE "84" BY "34" AND REPLACE "FANTELLI, LIA " BY "FANTETTI, LIA"

WWE Wipo information: entry into national phase

Ref document number: 2003587378

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2484070

Country of ref document: CA

Ref document number: 20038093375

Country of ref document: CN

Ref document number: 10512287

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2003224100

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2004/09452

Country of ref document: ZA

Ref document number: 200409452

Country of ref document: ZA

122 Ep: pct application non-entry in european phase